Michael joined Calyx as Chief Financial Officer in April 2022, bringing a wealth of executive-level experience level in both operations and finance to the organization. Prior to joining Calyx, he worked primarily in IT-enabled service companies that provided support to US federal, state, and local governments as well as commercial entities in the US and internationally. Michael has a proven track record of helping private equity-backed, mid-market companies grow.

 

 

Jamie joined Calyx in January 2020 as the Chief Operating Officer bringing deep, global experience in driving operational excellence and breakthrough financial results. His 25 years’ experience includes a variety of operations, manufacturing, and senior executive roles across the aerospace, engineering, and professional services sectors. Jamie is a Chartered Engineer and holds an MBA from the University of Warwick Business School.

 

 

Stephen Bravo, MD joined Calyx in March 2021, bringing more than 30 years of broad scientific experience to the organization. His expertise stems from having served as a board-certified diagnostic radiologist at highly acclaimed healthcare centers, as a senior faculty member at leading academic institutions, and as a trusted scientific advisor to numerous global pharmaceutical companies. An acknowledged expert in Neuroradiology, Musculoskeletal Radiology, and Interventional Radiology, Dr. Bravo has authored numerous publications and abstracts, holds licenses in three states, and has undertaken the role of principal investigator in over 100 clinical trials.

 

 

Michelle Ronan joined Calyx in April 2022, bringing expertise in developing and executing long-term strategic plans in the global eClinical market. She is an accomplished Head of Corporate Strategy and Development, with significant experience centred around private equity backed businesses, guiding teams through the different stages of a business’ lifecycle. Prior to joining Calyx, Michelle was part of the Executive Leadership team at Signant Health and CRF Health. Michelle is a Chartered Accountant and spent 15 years in M&A specialising in the Life Sciences sector.

 

 

John Blakeley joined Calyx as Chief Commercial Officer in January 2020 and brings more than 30 years of senior commercial leadership experience. His expertise in the eClinical solutions space stems from having held C-suite positions at CRF Health, Greenphire, and ERT. John is a seasoned and innovative sales leader who has a successful track record in building high-performing teams to develop creative clinical solutions for customers and drive revenue growth.

 

 

Purvesh Patel joined Calyx in November 2020 leading the Legal, Compliance, Quality, Information Security, Data Privacy and Corporate Development functions. He has nearly 20 years of in-house legal and international corporate transactions experience in highly regulated health and technology sectors. Purvesh has his JD from Case Western Reserve University School of Law and is a trusted business partner relied on by C-suite leaders and Boards to advise on strategic planning, managed growth and governance on a global scale.

 

 

Shelley Latham joined Calyx as Chief People Officer in January 2020 and brings 25 years of experience leading Human Resources across a broad range of organizations. Before joining Calyx, she served as CHRO at HealthTrust Europe LLP and held various senior positions leading HR functions and delivering strategic projects in healthcare and other sectors.  Shelley is a Chartered Fellow of the Institute of Personnel Development and holds an MBA from Nottingham Business School.

 

 

Richard Wallace joined Calyx as Chief Digital Information Officer in February 2021, bringing a wealth of experience from having established and implemented successful business and technology strategies across multiple organizations. Prior to joining Calyx, Richard was Global CIO of Kantar Media & Worldpanel (WPP Group) and has led several R&D transformation projects at IAG / British Airways, G4S & Santander. Richard holds a degree in Economics from the University of Newcastle and an Executive Diploma from the Saïd Business School, University of Oxford.

 

 

Peter has a wealth of experience in the use of imaging and other biomarkers for documenting the safety, efficacy, and effectiveness of new drugs in clinical trials. He leads Calyx’s Global Scientific and Medical Services team of over 75 scientists and is actively engaged in developing and implementing effective imaging strategies for global clinical development programs. He has authored numerous papers and is regularly involved in research presented at scientific meetings.

 

In leading the imaging component of oncology studies for Calyx’s global customers, Oliver leverages his experience from supporting over 600 clinical trials – with various indications, complexities, and in all phases of development – which led to the approval of over 20 oncology treatments. He is co-author of the immune-related response criteria (irRC, 2009), first author of irRECIST (2014), and co-author of Comparison of Assessments using RECIST and irRECIST by Eggleton P. et al. (2020).

 

Leveraging her training in medicine and radiology, Surabhi has led the imaging components of approximately 50 oncology trials – both solid tumors and hematology malignancies –  and provided consultation on complicated aspects of standardized response assessment criteria. Her expertise in Multiple Myeloma, Lymphoma, and CLL enables her to provide clear guidance to clinical trial sponsors and communicate complexities of criteria to independent reviewers to avoid heterogeneity.

 

Having held senior medical roles at global biopharmaceutical companies and CROs and having worked as an investigator, Manish has a wealth of experience in understanding and executing clinical trials from each stakeholder’s perspective. Manish is a well-established medical and scientific SME for imaging in clinical trial design and execution and has been instrumental in the incorporation of innovative study designs including but not limited to biomarkers including imaging. Manish also has the additional responsibility of leading the Calyx Data Science team focusing on variability analysis, data-driven quality monitoring, and predictive analytics.

 

As the Head of Calyx Musculoskeletal Imaging, Dr. Warner applies her 25+ years of medical imaging research experience and the expertise she’s gleaned from supporting over 200 imaging trials to help pharmaceutical companies and CROs succeed.  She holds certifications by the International Society for Clinical Densitometry (ISCD) as a Clinical Densitometrist and a DXA technologist as well as a Radiology Practicing Technologist License in the state of Utah.  Dr Warner’s musculoskeletal research has included the use of many different modalities for the assessment of bone metabolism including bone histomorphometry, 3-point bending, radiography, ultrasound, DXA, QCT, and high-resolution CT imaging.

 

Manuela is responsible for providing scientific advice on implementing medical imaging into clinical trials, conducting investigator, internal staff, and independent reviewer trainings, supporting the development of independent review charters, providing guidance to R&D and application development in the customization of image analysis software tools, and monitoring independent reviewer performance. Manuela has significant experience in leading and managing the imaging component of multiple neurology and oncology clinical trials, with expertise in applying neuro-oncology image assessment criteria such as RANO, iRANO, LANO, REiNS and volumetric analysis.

 

Farhan applies his extensive training and knowledge in bone loss mechanisms and imaging ‒ both in pre-clinical and clinical settings ‒ to leading and overseeing varied clinical trials involving the musculoskeletal system. He also serves as a subject matter expert in this area, contributing and facilitating protocol reviews as well as imaging-focused discussions with clients as well as consultation and networking with Key Opinion Leaders in the field.